$MBAV

M3-Brigade Acquisition V Corp.

No enriched coverage for $MBAV in the last 7 days.

No SEC Form 4 filings for $MBAV in the last 30 days.

Med

M3-Brigade Acquisition V Corp. 2025 Annual Report: Business Combination with ReserveOne, Shareholder Rights, and Key Risks Overview

M3-Brigade Acquisition V Corp. (MBAV) has released its 2025 Annual Report, detailing its ongoing pursuit of a business combination with ReserveOne, Inc. The report highlights significant risks for shareholders, including potential dilution, the conditional nature of the ReserveOne deal and PIPE financing, and risks associated with redemption rights and possible delisting from Nasdaq. Investors are advised to monitor the transaction closely due to the company's dependency on a successful combination and its status as a "shell company."

M3-Brigade Acquisition V (Nasdaq:MBAV) - Stock Analysis

M3-Brigade Acquisition V (MBAV) is a SPAC with a market cap of US$383.8 million, primarily focused on effecting business combinations as it does not have significant operations. The company recently announced a $1 billion reverse merger agreement with ReserveOne Inc. and has received funding updates. MBAV has shown stable share price volatility compared to the US market but has underperformed the broader US Market over the past year, while exceeding the US Capital Markets industry.

ReserveOne Announces Filing of Registration Statement on Form S-4 with the SEC for Proposed Business Combination with M3-Brigade Acquisition V Corp.

ReserveOne and M3-Brigade Acquisition V Corp. announced that ReserveOne Holdings, Inc. (Pubco) has filed a registration statement on Form S-4 with the SEC regarding their proposed business combination. The filing is a key step towards Pubco being listed on Nasdaq under the ticker symbol "RONE" after the transaction closes, subject to SEC review and shareholder approval. This move follows a previously announced confidential submission and aims to merge ReserveOne's digital asset investment focus with M3-Brigade's SPAC structure.